ArrayExpress Uploader0humanIMDM with 10% FBSMV4-11EPZ0047771day 2biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11EPZ0047772day 2biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11EPZ0047773day 2biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11vehicle1day 2biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11vehicle2day 2biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11vehicle3day 2biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11EPZ0047771day 4biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11EPZ0047772day 4biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11EPZ0047773day 4biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11vehicle1day 4biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11vehicle2day 4biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11vehicle3day 4biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11EPZ0047771day 6biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11EPZ0047772day 6biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11EPZ0047773day 6biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11vehicle1day 6biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11vehicle2day 6biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)IMDM with 10% FBSMV4-11vehicle3day 6biphenotypic B myelomonocytic leukemia (MLL-AF4 rearragenment)RPMI with 10% FBSMOLM-13EPZ0047771day 6acute myeloid leukemia (MLL-AF9 rearrangement)RPMI with 10% FBSMOLM-13EPZ0047772day 6acute myeloid leukemia (MLL-AF9 rearrangement)RPMI with 10% FBSMOLM-13EPZ0047773day 6acute myeloid leukemia (MLL-AF9 rearrangement)RPMI with 10% FBSMOLM-13vehicle1day 6acute myeloid leukemia (MLL-AF9 rearrangement)RPMI with 10% FBSMOLM-13vehicle2day 6acute myeloid leukemia (MLL-AF9 rearrangement)RPMI with 10% FBSMOLM-13vehicle3day 6acute myeloid leukemia (MLL-AF9 rearrangement)4127arrayexpress_sid4Cell lines bearing MLL translocations (MV4-11 and MOLM-13) were treated with a potent, selective inhibitor of the DOT1L histone methyl...E-GEOD-29828/profile/8773/arrayexpressuploader624cellhistoneDec.12, 2014FalseE-GEOD-29828_A-AFFY-44expression-profiling-of-mixed-lineage-leukemia-celExpression Profiling of Mixed Lineage Leukemia Cells Treated with a Potent Small-Molecule DOT1L InhibitorSep.16, 2014Cell lines bearing MLL translocations (MV4-11 and MOLM-13) were treated with a potent, selective inhibitor of the DOT1L histone methyl transferase. Treatment of MLL-rearranged cell lines with the DOT1L inhibitor selectively inhibits H3K79 methylation and blocks expression of leukemogenic genes. Here we provide expression profiling data of cells treated with DOT1L inhibitor or vehicle control. MV4-11 cells were treated with 3 uM EPZ004777 (DOT1L inhibitor) or vehicle control (0.1% DMSO) for 2, 4 and 6 days. MOLM-13 cells were treated with 3 uM EPZ004777 (DOT1L inhibitor) or vehicle control (0.1% DMSO) for 6 days. For each unique conditon, 3 biological replicates were generated for expression profiling.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-29828http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-29828/samples/